Company: RVRC
Filing Date: 2025-02-14
Form Type: S-1
Source: 0001213900-25-013823
Chunk: 155

Company: Revium Rx.
Filing Date: 2025-02-14
Form: S-1
Chunk 155
---
 Granted                            |     |                                 |          - |   |     |          |    - |     |           | - |     |         |         - |   |     |          |    - |     |           | - |
| Exercised                          |     |                                 |          - |   |     |          |    - |     |           | - |     |         |         - |   |     |          |    - |     |           | - |
| Forfeited                          |     |                                 | (1,490,000 | ) |     |          |    - |     |           | - |     |         |  (250,000 | ) |     |          | 0.40 |     |           | - |
| Outstanding at end of period       |     |                                 |  3,060,000 |   |     |          | 0.40 |     |           |   |     |         | 4,550,000 |   |     |          | 0.40 |     |           |   |
| Vested at end of period            |     |                                 |  3,060,000 |   |     |          | 0.40 |     |           |   |     |         | 3,921,875 |   |     |          | 0.40 |     |           |   |

<div align='center'>F-46</div>

REVIUM RX.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

U.S. dollars in thousands, except share and per share data

NOTE 7 – STATEMENTS OF OPERATIONS DATA

| a. | Research and development expenses: |

|                                |     | Year ended  December 31, | 2023 |     |     | 2022 |
|:-------------------------------|:----|:-------------------------|-----:|:----|:----|-----:|
| Subcontractors and consultants |     |                          |    7 |     |     |   51 |
| Payroll and related expenses   |     |                          |    - |     |     |   16 |
|                                |     |                          |    7 |     |     |   67 |

| b. | General and administrative expenses: |

|                                  |     | Year ended  December 31, | 2023 |     |     |  2022 |
|:---------------------------------|:----|:-------------------------|